Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.
| Revenue (TTM) | $22.53M |
| Gross Profit (TTM) | $8.50M |
| EBITDA | $-11.62M |
| Operating Margin | -128.40% |
| Return on Equity | -15.80% |
| Return on Assets | -13.40% |
| Revenue/Share (TTM) | $1.38 |
| Book Value | $2.77 |
| Price-to-Book | 1.28 |
| Price-to-Sales (TTM) | 2.09 |
| EV/Revenue | 1.841 |
| EV/EBITDA | 8.68 |
| Quarterly Earnings Growth (YoY) | 433.30% |
| Quarterly Revenue Growth (YoY) | -59.30% |
| Shares Outstanding | $16.46M |
| Float | $13.55M |
| % Insiders | 17.63% |
| % Institutions | 27.75% |
Volatility is currently expanding
Sensus Healthcare NASDAQ: SRTS reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June.
Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un.
Sensus Healthcare NASDAQ: SRTS said its first quarter of 2026 marked a transition period as new dedicated CPT codes for superficial radiotherapy took effect, while revenue declined from the prior year due largely to the absence of sales to its historically largest customer.
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced that SkinCure Oncology and Sensus Healthcare have amicably resolved their dispute and are moving forward constructively with a shared commitment to patient care and clinical excellence. In March 2026, Sensus Healthcare filed a lawsuit in the Circuit Court for the Fifteenth Judicial Cir.
Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Transcript
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: Revenue of $3.4 million compared to $8.3 million for the three months ended March 31, 2025. Excluding sales to the Company's historically largest customer, rev.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SRTS and any ticker you trade — then tracks every position and per-strategy win rate.
